Recursion Pharmaceuticals AI Platform

Recursion Pharmaceuticals combined robotics, high-content imaging, and machine learning to test 2.2 million compound-disease combinations per week in its Salt Lake City laboratory — a throughput 1,000x greater than traditional drug discovery methods. Its AI identified novel indications for existing drugs (drug repurposing), with REC-994 for cerebral cavernous malformation entering Phase II trials as the first fully AI-discovered drug candidate in neurological disease.